Detailed Rationale

Crisil Ratings has revised its outlook on the long-term bank facilities of Laxmi Organic Industries Ltd (LOIL) to ‘Negative’ from ‘Stable’ while reaffirming the rating at ‘Crisil AA’. Crisil Ratings has also reaffirmed its ‘Crisil A1+’ rating on the short-term bank facilities and commercial paper of the company.

 

The revision in outlook follows continuing sluggish revenue and significant decline in operating profitability especially in the specialty chemical (28% of revenue; 72% of earnings before interest taxes depreciation and amortisation [Ebitda]) while the drop in revenue and profitability in the essential division (72% of revenue; 28% of Ebitda) was not as pronounced. Factors such as decline in realisations (specialty and essential), deferment of sales on some high-margin products and on account of phase-out of a high-margin agrochemical product, resulted in revenue dipping by 6% to Rs 1,393 crore, in the first half of fiscal 2026 (Rs 1,489 crore in the corresponding half of fiscal 2025), while operating profitability halved to 4.9% from 9.8%, impacting cash generation. Revenue in fiscal 2026 should be aided by incremental revenue from the essential capacities at Dahej (Gujarat), which was commercialised towards the end of the second quarter of fiscal 2026 as well as incremental revenue from fluorochemical (Miteni) and the expected realisation of sales of certain products that were deferred in the first half. However, revenues in fiscal 2026 are expected to be below prior expectations. Nevertheless, revenue may increase to Rs 4,000-4,400 crore over the medium term, driven by stable revenue from existing capacities, the ramp-up of newly added capacities in both essentials and the specialty segment, fluorochemical ramp-up at Lote, and incremental revenue from a new contract signed with Hitachi. Hence, operating profitability is expected to improve in the second half of the current fiscal; however, its improvement trajectory will remain monitorable. Over the medium term, with the benefits of operating leverage accruing from the ramp-up of new capacities, the operating margin may improve to 9-11%, also benefitting Ebitda, which though will still remain substantially lower than earlier envisaged.

 

Return on capital employed (RoCE) may decline to mid-single digit this fiscal from 8.5% in fiscal 2025 due to steep reduction in profitability and high capital expenditure (capex) being incurred over the past few fiscals. RoCE is also expected to be lower than previously anticipated. With expected improvement in profitability and no major capex, RoCE is expected to improve to high single to low double digits over the medium term

 

The company is likely to incur capex of over Rs 700 crore in fiscal 2026, of which ~Rs 550 crore may be deployed for the Dahej plant and the balance towards the Lote plant (ethyl acetate, Hitachi) and maintenance and debottlenecking. Post this fiscal, capex will be moderate at Rs 150-200 crore, which will largely be deployed towards maintenance/debottlenecking and minor capacity additions.

 

Financial risk profile remains strong, marked by healthy capital structure and comfortable debt protection metrics. LOIL had healthy tangible networth of Rs 1,928 crore as on September 30, 2025, (March 31, 2025: Rs 1,906 crore) as against debt of Rs 330 crore (Rs 253 crore), resulting in healthy gearing of 0.17 time (0.13 time). Despite expected additional debt for the Dahej capex, adjusted gearing is still expected to remain below 0.5 time in the near to medium term. Likewise, total outside liabilities to tangible networth (TOL/TNW) ratio is also expected to sustain below 0.9 time over the medium term (March 31, 2025: 0.9 time). Adjusted interest coverage deteriorated to 7.29 times in the first half of fiscal 2026, from 15.02 times in the first half of fiscal 2025, due to steep decline in profitability. With expected improvement in profitability partly offset by expected higher interest expense, interest coverage is expected to improve and sustain at 9-11 times in the near to medium term. LOIL is expected to generate net cash accrual of Rs 250-300 crore over the medium term, adequate to meet repayment obligations of Rs 30-35 crore. As on September 30, 2025, the company maintained healthy unencumbered liquid surplus of Rs 142 crore. Also, it had unutilised bank lines of Rs 467 crore for the 12 months through October 2025, which provides additional cushion.

 

The ratings continue to reflect LOIL’s strong market position across two verticals, essentials and specialty chemicals, diversified end-user industries base resulting in low customer concentration risk and healthy financial risk profile. These strengths are partially offset by susceptibility to fluctuations in input prices and foreign exchange (forex) rates and exposure to risk pertaining to timely execution of the large capex being undertaken.

Analytical Approach

Crisil Ratings has combined the business and financial risk profiles of LOIL and its subsidiaries as the entities have similar businesses.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers - Strengths 

Strong market position with healthy market share in key product segments

LOIL is a leading manufacturer of ethyl acetate and acetic acid derivatives, which are key solvents used across industries (essentials business), and diketene derivatives products (speciality chemicals business). The company has a track record of more than 35 years in the ethyl acetate segment and has weathered the seasonality inherent in the sector. It is also the seventh-largest manufacturer of ethyl acetate globally, with a capacity of over 2,42,000 metric tonne per annum, according to the management. In the essentials segment, LOIL commands ~34% market share in ethyl acetate and its closest competitor is Jubilant Ingrevia Ltd (‘Crisil A1+’). In the diketene derivatives segment, LOIL meets close to 55% of domestic demand. LOIL operates in segments that have high entry barriers. The essentials business requires cost competitiveness while the specialties business has high entry barriers due to complex chemistries and high capital investment towards technology and research and development (R&D) infrastructure.

 

Well-diversified end-user base and low customer concentration risk

LOIL caters to diverse end users with its products finding applications in various high-growth industries, including pharmaceuticals, agrochemical, dyes and pigments, inks and coatings, paints, printing and packaging, flavours and fragrances, adhesives and other industrial applications. No single segment contributes more than 30% of revenue. Also, no single customer contributed more than 10% of revenue in fiscal 2025 rendering limited dependence on a customer. Revenue share from top customers decreased to 21% in first half of fiscal 2026, from 23% in fiscal 2025. This also ensures less vulnerability in revenue.

 

Healthy financial risk profile

Financial risk profile remains strong, marked by healthy tangible networth of Rs 1,928 crore as on September 30, 2025 (March 31, 2025: Rs 1,906 crore), as against debt of Rs 330 crore (Rs 253 crore), resulting in healthy gearing of 0.17 time (0.13 time). Despite expected increase in debt levels, with expected improvement in profitability and progressive repayment of debt, gearing and the TOL/TNW ratio are expected to strengthen and sustain below 0.4 time and 0.9 time respectively over the medium term. While debt protection metrics such as interest coverage and net cash accrual to total debt are expected to moderate this fiscal owing to decline in profitability, the metrics may improve to 9-11 times and 0.4-0.6 time respectively over the medium term.

Key Rating Drivers - Weaknesses 

Susceptibility to volatility in forex rates and raw material prices 

Fluctuation in raw material prices (acetic acid and ethanol) have a direct bearing on revenue. For example, in fiscal 2022, acetic acid prices rose sharply due to which revenue of LOIL also increased. Post fiscal 2022, when acetic acid prices moderated, revenue growth moderated despite volume growth. Ethyl acetate (part of the essentials segment, which contributes 65-70% of revenue) is a commodity product, and thus, is vulnerable to volatility in raw material prices, which are governed by global supply-demand dynamics. Also, the price of acetic acid is cyclical as it is linked to natural gas prices. Similarly, the price of ethyl alcohol, derived from sugarcane molasses/grain, is cyclical. LOIL is vulnerable to forex fluctuations as it imports the raw materials (acetic acid and ethyl alcohol). However, the company’s exports provide a natural hedge to some extent. Furthermore, LOIL uses forward contracts to mitigate the risk.

 

Exposure to project implementation risks

The company is in the process of executing a major capex at Dahej aggregating ~Rs 1,100 crore between fiscals 2025 and 2026 at its Dahej and Lote facilities, which will be largely deployed towards doubling its diketene derivatives capacities and expanding and diversifying its essentials product portfolio. Phase I of capex was completed by end of second quarter of fiscal 2026 and phase II is likely to be completed by end of the fourth quarter of fiscal 2026. LOIL completed capex of ~Rs 550 crore in the previous fiscal for transferring the assets and technology acquired from Miteni SpA, an Italian manufacturer, whose assets were acquired in June 2019. The capex was planned for completion in fiscal 2022 for Rs 250-300 crore but was finally executed in fiscal 2024, with cost overrun of nearly Rs 250 crore, which moderated the ROCE. Given the sizeable capex being undertaken, any significant time or cost overrun may constrain the RoCE and liquidity and financial risk profiles of the company. Hence, timely execution of the capex without any significant cost overrun will remain a key monitorable.

Liquidity Strong

LOIL is expected to generate net cash accrual of Rs 250-300 crore per annum, which will be adequate to meet the yearly repayment obligation of Rs.30-35 crore over the medium term. As on September 30, 2025, the company maintained healthy unencumbered liquid surplus of Rs 142 crore. Also, it had unutilised bank lines of over Rs 400 crore based on its average limit utilisation for 12 months through October 2025, which provides additional cushion.

Outlook Negative

The Negative outlook reflects the moderation in the operating efficiency profile owing to decline in operating margin, led by contraction in realisations amidst sustained pricing pressure across both key verticals. Financial risk profile is likely to remain comfortable over the medium term, supported by healthy capital structure, debt protection metrics and strong liquidity. Any further weakening in profitability impacting cash generation will remain a key monitorable.

Rating sensitivity factors

Upward factors

• Significant increase in scale of operations and improvement in operating profitability, leading to increase in RoCE to over 20% on a sustained basis
• Sustenance of strong financial risk profile, robust debt protection metrics and healthy liquidity

 

Downward factors

• Sluggish revenue growth and operating margin declining below 7-9% on a sustained basis
• Sizeable additional, debt-funded capex or acquisitions or stretched working capital cycle, materially impacting the debt metrics
• Significant delay in commissioning new projects, resulting in major cost overrun

About the Company

LOIL is a Mumbai-based company, promoted by Mr Vasudeo Goenka. It was incorporated in 1989 and commenced manufacturing acetic acid at Mahad, Maharashtra, in 1991. It has diversified into other products and now primarily manufactures ethyl acetate, acetic acid and diketene derivative products. Diketene derivative products are a specialty chemical group, the technology and business of which was acquired by LOIL from Clariant Chemicals India Ltd (Clariant) in 2010. Pursuant to the Clariant acquisition, the company acquired the technology and know-how of 18 products from Clariant, of which the company is producing 16 products under the specialty intermediates product portfolio. Through R&D efforts, in addition to the products acquired from Clariant, LOIL has added 30 new products to the specialty intermediates portfolio over the last decade and expanded its product portfolio to over 50 products. Recently, the company forayed into fluorochemicals (commercial production began from the second half of this fiscal).

 

The company serves over 620 customers across North America, South America, the UK, Europe, Africa, Asia and Australia. Revenue contribution from export was close to 30% of sales in the first half of fiscal 2026 and Europe remained a key export revenue contributor at 39%, followed by America (26%), the Middle East (13%), Africa (6%) and rest of the world (19%). It serves a diverse set of customers from industries such as pharmaceuticals, adhesives, inks and paints, coatings, printings, packaging, dyes and pigments, automotive, flavors and fragrances.

 

During the first half of fiscal 2026, LOIL reported a 6% decline in revenue of Rs 1,393 crore (from Rs 1,489 crore in the first half of fiscal 2025); PAT during the first half of fiscal 2026 was Rs 32 crore as against Rs 62 crore in the corresponding period of the previous fiscal.

Any other information: Not applicable